Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to validate an integrated pharmacokinetic-pharmacodynamic model to administer propofol in obese patients.

Our hypothesis is that pharmacokinetic and pharmacodynamic changes occur with increasing weight and that mathematical models to administer drugs in obese patients can be developed to accurately predict dose schemes in this population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pontificia Universidad Catolica de Chile
• Treatments: Propofol

Criteria

Inclusion Criteria:

• IMC > 35 kg m-2

• Scheduled for laparoscopic bariatric surgery

• ASA I-II patients

• Between 18 and 60 yr of age.

Exclusion Criteria:

• Patients with allergy to study drugs

• Uncontrolled hypertension

• Heart block greater than first degree

• Take any drug acting in the central nervous system within 24 hrs before surgery.